Fundraising Fox
🦊/Companies
Sign in

Complix

5 known investors

Find your way into Complix

Complix develops therapeutic biologics based on Alphabody technology targeting viral diseases, oncology, and autoimmune conditions. The company focuses on cell-penetrating therapeutics designed to reach intracellular disease targets.

AI & Machine LearningBiotechDeep TechMedical Devices

Investors · 5

PMV✓ verifiedBrussels
Andera PartnersParis
Vesalius Biocapital PartnersLuxembourg · $11M
GimvreportedAntwerp · $21M – $430M
Omnes CapitalreportedParis

Competitors · 1

by search overlap
Exelixis3 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

Companies competing with Complix for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

BioCentury - Complix raises EUR 12 million in series Bbiocentury.com · Jun 2013Belgian biotech Complix raises $15M for 'Alphabody' R&D work | Fierce Biotechfiercebiotech.com · Jun 2013Complix Closes €12M Series B Equity Financing - FinSMEsfinsmes.com · Jun 2013Complix Raises €12 Million (US$15.5 million) in Series B Roundprnewswire.com · Jun 2013Complix NV Raises $15.5 Million in Series B Round - BioSpacebiospace.com · Jun 2013Belgium-Based Complix NV Raises Eur 5 Million - BioSpacebiospace.com · Jun 2010

Frequently asked questions

What does Complix do?
Complix develops therapeutic biologics based on Alphabody technology targeting viral diseases, oncology, and autoimmune conditions. The company focuses on cell-penetrating therapeutics designed to reach intracellular disease targets.
Who are Complix's investors?
Complix's investors include PMV, Andera Partners, Vesalius Biocapital Partners, Gimv, Omnes Capital.